Morgan Stanley has revised its rating for ResMed, a company specializing in cloud-connected devices for people with sleep apnea and chronic obstructive pulmonary disease, due to concerns regarding its profit margins. The downgrade reflects apprehensions about the company's ability to maintain its current margin levels amid competitive pressures and market conditions. Investors are advised to consider these factors as they assess the stock's potential performance moving forward.
Related Articles
Don't miss out on breaking stories and in-depth articles.